利妥昔单抗治疗皮质类固醇抵抗性复发性IgG4相关性颅内硬脑膜炎：两例报告
Rituximab for corticosteroid-resistant relapsing IgG4-related intracranial pachymeningitis: report of two cases.
作者信息
Mageau Arthur, Shor Natalia, Fisselier Matthieu, Aboab Jennifer, Lecler Augustin, Rebours Celeste, Adle-Biassette Homa, Gout Olivier, Deschamps Romain
机构信息
Department of Neurology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France.
Department of Radiology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, Île-de-France, France.
出版信息
Pract Neurol. 2018 Apr;18(2):159-161. doi: 10.1136/practneurol-2017-001826. Epub 2017 Dec 5.
IgG4-related disease is now recognised as an important cause of intracranial and spinal hypertrophic pachymeningitis. Treatment with corticosteroids generally leads to significant clinical improvement. We present two cases of IgG4 pachymeningitis unresponsive to corticosteroids who improved with rituximab.
IgG4相关疾病目前被认为是颅内和脊髓肥厚性硬脑膜炎的重要病因。使用皮质类固醇进行治疗通常会使临床症状得到显著改善。我们报告了两例对皮质类固醇无反应的IgG4硬脑膜炎患者，他们使用利妥昔单抗后病情得到改善。
Zotero 插件